Porton Advanced, EVA Pharma Sign MOU to Expand CAR T-Cell Therapy in MEA Region

Porton Advanced Solutions, a global leader in cell and gene therapy contract development and manufacturing (CDMO), has signed a Memorandum of Understanding (MOU) with EVA Pharma, a prominent pharmaceutical company in the Middle East and Africa (MEA), to expand access to CAR T-cell therapy in the region.

The collaboration aims to establish and enhance CAR T-cell therapy development and manufacturing at EVA Pharma’s facilities, with a focus on producing high-quality lentiviral vectors—critical components used in treating leukemia and other blood cancers.

Under the agreement, Porton Advanced will provide its specialized expertise in viral vector and CAR T-cell therapy manufacturing to support EVA Pharma’s expansion into advanced cancer treatment. By combining Porton Advanced’s technical know-how with EVA Pharma’s established infrastructure and regional leadership, the partnership seeks to enable local production of cutting-edge immunotherapies.

“Patients battling cancer deserve more than hope; they deserve access to innovations once thought out of reach,” said Riad Armanious, CEO of EVA Pharma. “Together, EVA Pharma and Porton Advanced are combining our capabilities to localize innovation—at scale and with equity.”

Andrew Chen, CFO of Porton Advanced, added, “We are excited to collaborate with EVA Pharma to make transformative cell therapies more accessible. This partnership marks a sustainable model for advanced therapy manufacturing in emerging markets.”

The initiative supports broader global efforts to democratize access to next-generation immunotherapies. With plans to develop manufacturing hubs in Egypt and Saudi Arabia, the partnership aims to reduce treatment costs, accelerate production timelines, and raise the standard of oncology care in the MEA region.